BioMarin Pharmaceutical (BMRN) reported Q1 non-GAAP earnings late Thursday of $1.13 per diluted share, up from $0.71 a year earlier.
Analysts polled by FactSet expected $0.95.
Revenue in the three months ended March 31 rose to $745.1 million from $648.8 million a year earlier.
Analysts surveyed by FactSet expected $738.7 million.
The company reiterated 2025 non-GAAP diluted EPS guidance of $4.20 to $4.40, on revenue of $3.1 billion to $3.2 billion. Analysts polled by FactSet expect EPS of $4.30 on revenue of $3.14 billion.
Shares of BioMarin rose 1.1% in after-hours trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。